These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10718490)

  • 1. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma.
    Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
    Breast Cancer Res Treat; 1999 Dec; 58(3):287-93. PubMed ID: 10718490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase-2 (MMP-2) is associated with the risk for a relapse in postmenopausal patients with node-positive breast carcinoma treated with antiestrogen adjuvant therapy.
    Talvensaari-Mattila A; Pääkko P; Blanco-Sequeiros G; Turpeenniemi-Hujanen T
    Breast Cancer Res Treat; 2001 Jan; 65(1):55-61. PubMed ID: 11245340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic role of interleukin-8 (IL-8) and matrix metalloproteinases -2 and -9 in lymph node-negative untreated breast cancer patients.
    Milovanovic J; Todorovic-Rakovic N; Abu Rabi Z
    J BUON; 2013; 18(4):866-73. PubMed ID: 24344010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma.
    Li HC; Cao DC; Liu Y; Hou YF; Wu J; Lu JS; Di GH; Liu G; Li FM; Ou ZL; Jie C; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2004 Nov; 88(1):75-85. PubMed ID: 15538048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-2 (MMP-2) in T(1-2)N0 breast carcinoma.
    Hirvonen R; Talvensaari-Mattila A; Pääkkö P; Turpeenniemi-Hujanen T
    Breast Cancer Res Treat; 2003 Jan; 77(1):85-91. PubMed ID: 12602907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastasis-related factors expressed in pT1 pN0 breast cancer: assessment of recurrence risk.
    Ogura S; Ohdaira T; Hozumi Y; Omoto Y; Nagai H
    J Surg Oncol; 2007 Jul; 96(1):46-53. PubMed ID: 17385712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast.
    Sullu Y; Demirag GG; Yildirim A; Karagoz F; Kandemir B
    Pathol Res Pract; 2011 Dec; 207(12):747-53. PubMed ID: 22030137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer].
    Zhang B; Liu YX; Cao WF; Cao XC; Ning LS; Hao XS
    Zhonghua Bing Li Xue Za Zhi; 2008 Jul; 37(7):471-6. PubMed ID: 19035119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer.
    Won HS; Lee KE; Sung SH; Choi MY; Jo JY; Nam EM; Mun YC; Seong CM; Lee SN
    Tumori; 2014; 100(1):80-6. PubMed ID: 24675496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma--tissue immunoreactivity predicts aggressive clinical course.
    Ruokolainen H; Pääkkö P; Turpeenniemi-Hujanen T
    Mod Pathol; 2006 Feb; 19(2):208-17. PubMed ID: 16424893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary testosterone as a marker of risk of recurrence in operable breast cancer.
    Ballerini P; Oriana S; Duca P; Martinetti A; Venturelli E; Ferrari L; Dolci S; Secreto G
    Breast Cancer Res Treat; 1993; 26(1):1-6. PubMed ID: 8400317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative serum MMP-9 immunoreactive protein is a prognostic indicator for relapse-free survival in breast carcinoma.
    Talvensaari-Mattila A; Turpeenniemi-Hujanen T
    Cancer Lett; 2005 Jan; 217(2):237-42. PubMed ID: 15617842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment.
    Linderholm B; Grankvist K; Wilking N; Johansson M; Tavelin B; Henriksson R
    J Clin Oncol; 2000 Apr; 18(7):1423-31. PubMed ID: 10735889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometric DNA ploidy defines patients with poor prognosis in node-negative breast cancer.
    Balslev I; Christensen IJ; Rasmussen BB; Larsen JK; Lykkesfeldt AE; Thorpe SM; Rose C; Briand P; Mouridsen HT
    Int J Cancer; 1994 Jan; 56(1):16-25. PubMed ID: 8262673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of cytosolic p53 protein in breast cancer.
    Montero S; Guzmán C; Vargas C; Ballestín C; Cortés-Funes H; Colomer R
    Tumour Biol; 2001; 22(5):337-44. PubMed ID: 11553865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.